Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Beta Bionics, Inc

Get SEC filing alerts via email and in your feed for Beta Bionics, Inc

BBNX

Beta Bionics, Inc

About Beta Bionics, Inc

Beta Bionics designs and commercializes innovative medical devices, primarily focused on automated insulin delivery systems for people with diabetes. Its flagship product, the iLet Bionic Pancreas, autonomously manages insulin dosing, simplifying diabetes treatment and improving glycemic control. The company targets Type 1 and potentially Type 2 diabetes markets, leveraging advanced algorithms, strategic partnerships, and a scalable platform to enhance patient outcomes and device accessibility.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Beta Bionics, Inc

1
1
Beta Bionics, Inc Beta Bionics Reports 57% Revenue Growth to $27.6 Million in Latest Quarter

Via official filing (AI summary) | about 2 months ago | 0 comments

2
1
Beta Bionics, Inc Beta Bionics Reports 54% Revenue Growth to $100.3 Million in Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Beta Bionics, Inc Beta Bionics Reports 63% Revenue Growth to $27.3 Million Despite Increased Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Beta Bionics, Inc Beta Bionics Reports 54% Revenue Growth to $23.2 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Beta Bionics, Inc Beta Bionics Reports $28.6 Million Net Loss and $17.6 Million in Sales for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments